Drug Trial Radar · NCT06162338
A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
Last checked: Nov 20, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3
Planned (sponsor's estimate)
Start
Nov 15, 2023
Primary completion
Dec 17, 2026
Study completion Dec 17, 2031
Sponsor
- Lead sponsor
- He HuangAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Lingyi Biotech Co., Ltd.
- First posted
- Dec 8, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective single-center, open, single-arm, single-dose intravenous infusion study to evaluate the safety and initial efficacy, pharmacodynamic characteristics, immunogenicity, biodistribution, and viral shedding of LY-M001 injection.This study mainly includes the main study stage and the long-term follow-up study stage.
Conditions
- Gaucher Disease Type I
Interventions
LY-M001 InjectionBiological
With 5.0 × 10\^12 vg/kg as the initial effective dose (first dose group), 1 to 2 subjects are expected to be included. The first dose group was enrolled by sentinel method, and the first subject in this group was observed for at least 28 days after receiving LY-M001 (dose-limited toxicity \[DLT\] observation period) to enroll the next subject. After the first participant completes the safety evaluation of dosing for at least 28 days, the investigator (PI) and the partner discuss the safety and efficacy data and decide to maintain the first dose or increase/reduce it to another dose group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment- related adverse eventsTime frame: within 38 weeks after LY-M001 infusion
- Incidence of events adjudicated as dose limiting toxicity (DLT)Time frame: within 28 days after LY-M001 infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhejiang University School of Medicine
Hanzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.